Metabolix initiates public offering of common stock

NewsGuard 100/100 Score

Metabolix, Inc. (NASDAQ: MBLX), a bioscience company focused on developing sustainable solutions for plastics, chemicals and energy, today announced that it has commenced a public offering of shares of its common stock pursuant to the Company's effective shelf registration statement filed with the U.S. Securities and Exchange Commission (the "SEC").

J.P. Morgan Securities LLC will serve as the sole book-running manager and Stifel Nicolaus Weisel will serve as the co-manager for this offering. The Company expects to offer 4.75 million newly issued shares. The underwriters also have the option to purchase up to an additional 15% percent of the offered amount of common stock from the Company at the public offering price, less underwriting discounts and commissions, within 30 days, to cover over-allotments, if any. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. The Company intends to use the net proceeds it receives from the offering for working capital and other general corporate purposes.

SOURCE Metabolix, Inc.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Microfluidic chips advance neurodegenerative disease research